Cargando…
Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients
BACKGROUND: Diabetes mellitus is a chronic metabolic disorder of hyperglycemia. Chronic hyperglycemia produces advanced glycation end products such as the methylglyoxal (MGO) which interferes with cell functions, insulin signaling, and β-cell functions. The present study was conducted to determine t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327683/ https://www.ncbi.nlm.nih.gov/pubmed/30693045 http://dx.doi.org/10.4103/jrms.JRMS_1078_17 |
_version_ | 1783386514643746816 |
---|---|
author | Memon, Muhammad Ayoob Khan, Raisa Noor Riaz, Saman Ain, Qurat Ul Ahmed, Masood Kumar, Naresh |
author_facet | Memon, Muhammad Ayoob Khan, Raisa Noor Riaz, Saman Ain, Qurat Ul Ahmed, Masood Kumar, Naresh |
author_sort | Memon, Muhammad Ayoob |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus is a chronic metabolic disorder of hyperglycemia. Chronic hyperglycemia produces advanced glycation end products such as the methylglyoxal (MGO) which interferes with cell functions, insulin signaling, and β-cell functions. The present study was conducted to determine the effects of berberine (BBR) therapy on serum MGO and insulin resistance in newly diagnosed type 2 diabetic patients. MATERIALS AND METHODS: The present case–control study was conducted at the Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro/Hyderabad, from March 2016 to January 2017. A sample of 200 newly diagnosed type 2 diabetic patients was divided into two groups. Group 1 received metformin 500 mg (×3 daily) and Group 2 received BBR 500 mg (×3 daily) for 3 months. Blood samples were collected at baseline and after 3 months to analyze biochemical parameters on Roche biochemical analyzer. MGO was assayed by ELISA kit and homeostasis model assessment of insulin resistance (HOMA-IR) model. SPSS version 23.0 (IBM, Incorporation, USA) analyzed the data at 95% confidence interval (P ≤ 0.05). RESULTS: Baseline HOMA-IR (% IR) and MGO were found elevated in metformin and BBR groups. After 3 months of metformin and BBR therapy, the HOMA-IR (% IR) and MGO were decreased to 3.69 ± 1.13 and 2.64 ± 0.76 and 35.84 ± 12.56 and 26.64 ± 10.73 ng/dl, respectively (P = 0.0001). HOMA-IR (% IR) was improved by 40% and 73% (P = 0.0001) and MGO by 43% and 56% in metformin and BBR groups, respectively (P = 0.0001). CONCLUSION: BBR is more effective in decreasing the serum MGO levels and insulin resistance through improved glycemic control in newly diagnosed type 2 diabetic patients. |
format | Online Article Text |
id | pubmed-6327683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63276832019-01-28 Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients Memon, Muhammad Ayoob Khan, Raisa Noor Riaz, Saman Ain, Qurat Ul Ahmed, Masood Kumar, Naresh J Res Med Sci Original Article BACKGROUND: Diabetes mellitus is a chronic metabolic disorder of hyperglycemia. Chronic hyperglycemia produces advanced glycation end products such as the methylglyoxal (MGO) which interferes with cell functions, insulin signaling, and β-cell functions. The present study was conducted to determine the effects of berberine (BBR) therapy on serum MGO and insulin resistance in newly diagnosed type 2 diabetic patients. MATERIALS AND METHODS: The present case–control study was conducted at the Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro/Hyderabad, from March 2016 to January 2017. A sample of 200 newly diagnosed type 2 diabetic patients was divided into two groups. Group 1 received metformin 500 mg (×3 daily) and Group 2 received BBR 500 mg (×3 daily) for 3 months. Blood samples were collected at baseline and after 3 months to analyze biochemical parameters on Roche biochemical analyzer. MGO was assayed by ELISA kit and homeostasis model assessment of insulin resistance (HOMA-IR) model. SPSS version 23.0 (IBM, Incorporation, USA) analyzed the data at 95% confidence interval (P ≤ 0.05). RESULTS: Baseline HOMA-IR (% IR) and MGO were found elevated in metformin and BBR groups. After 3 months of metformin and BBR therapy, the HOMA-IR (% IR) and MGO were decreased to 3.69 ± 1.13 and 2.64 ± 0.76 and 35.84 ± 12.56 and 26.64 ± 10.73 ng/dl, respectively (P = 0.0001). HOMA-IR (% IR) was improved by 40% and 73% (P = 0.0001) and MGO by 43% and 56% in metformin and BBR groups, respectively (P = 0.0001). CONCLUSION: BBR is more effective in decreasing the serum MGO levels and insulin resistance through improved glycemic control in newly diagnosed type 2 diabetic patients. Medknow Publications & Media Pvt Ltd 2018-12-28 /pmc/articles/PMC6327683/ /pubmed/30693045 http://dx.doi.org/10.4103/jrms.JRMS_1078_17 Text en Copyright: © 2018 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Memon, Muhammad Ayoob Khan, Raisa Noor Riaz, Saman Ain, Qurat Ul Ahmed, Masood Kumar, Naresh Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title | Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title_full | Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title_fullStr | Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title_full_unstemmed | Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title_short | Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
title_sort | methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327683/ https://www.ncbi.nlm.nih.gov/pubmed/30693045 http://dx.doi.org/10.4103/jrms.JRMS_1078_17 |
work_keys_str_mv | AT memonmuhammadayoob methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients AT khanraisanoor methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients AT riazsaman methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients AT ainquratul methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients AT ahmedmasood methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients AT kumarnaresh methylglyoxalandinsulinresistanceinberberinetreatedtype2diabeticpatients |